FLONASE® ALLERGY RELIEF CLINICAL PROFILE

FLONASE® ALLERGY RELIEF CLINICAL PROFILE


Proven To Relieve Itchy, Watery Eyes1

CLINICIAN REPORTED: Significant Relief of Total Ocular 
Symptom Scores (TOSS)1

P<0.001
>40% improvement in TOSS from baseline at day 7.1

At both days 7 and 14 of the study, FLONASE® provided significant relief of itching and tearing1

PATIENT REPORTED: Significant Relief of Overall Ocular Scores1

Significant relief of ocular symptoms at week 1 and week 21

At both weeks 1 and 2 of the study, FLONASE® provided1:

  • Significant relief of itching and tearing 


What is Total Ocular Symptom Score (TOSS)?

TOSS is determined by an analysis of the following symptoms1:

  • Itching
  • Tearing
  • Redness
  • Puffiness

Onset of Action

For some patients, 24-hour relief begins with the first dose2-4

  • In some patients, FLONASE® Allergy Relief starts to act in 2 to 4 hours 2-4
  • Most patients will have achieved some relief in 12 hours2-4
  • Notable symptom improvement in 24 hours2-4
  • Maximum benefit achieved in 3 to 4 days2-4

For maximum benefit, advise patients to continue taking FLONASE® Allergy Relief for 3 to 4 days, then make it part of their daily routine as long as they are exposed to allergens.5-7 

A well-established safety profile trusted by doctors and pharmacists for over 20 years8-11

FLONASE® Allergy Relief has a well-established safety profile.

FLONASE® is a corticosteroid with low (<1%) systemic absorption12,13

  • Minimizes potential for systemic side effects that are a concern with other corticosteroids such as prednisone12-15

FLONASE® Allergy Relief is NOT associated with:

  • Higher blood pressure and is not contraindicated in patients with hypertension, heart disease, diabetes, liver disease, or kidney disease14-20
  • Anticholinergic side effects commonly associated with some other allergy medications, such as drowsiness, dry mouth, nervousness, dizziness, or sleeplessness14-20

RESOURCES

Patient education materials and more

PATIENT TYPES

Explore different patient types and find out which product is right for your patients

DOSING

Learn more about FLONASE® Allergy Relief Administration and Dosing

References

1. DeWester, J., Philpot, E. E., Westlund, R. E., Cook, C. K. et al. The Efficacy of Intranasal Fluticasone Propionate in the Relief of Ocular Symptoms Associated With Seasonal Allergic Rhinitis. Allergy and Asthma Proceedings. 24(5): 331-337, 2003. 2. Meltzer, E. O., Rickard, K. A., Westlund, R. E., and Cook, C. K. Onset of Therapeutic Effect of Fluticasone Propionate Aqueous Nasal Spray. Annals of Allergy, Asthma and Immunology. 86(3): 286-291, 2001. 3. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study FLN-444. Http://Www.Gsk-Clinicalstudyregister.Com/. 12-19-2005.) 4. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study FLN-445. Http://Www.Gsk-Clinicalstudyregister.Com/. 12-14-2005.) 5. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study R1810220. Http://Www.Gsk-Clinicalstudyregister.Com/. 6-29-2005.) 6. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study R1810221. Http://Www.Gsk-Clinicalstudyregister.Com/. 6-29-2005.) 7. FLONASE® Drug Facts Label. 8. Van As, A., Bronsky, E., Grossman, J., Meltzer, E. et al. Dose Tolerance Study of Fluticasone Propionate Aqueous Nasal Spray in Patients With Seasonal Allergic Rhinitis. Annals of Allergy. 67(2 I): 156-162, 1991. 9. Meltzer, E. O., Orgel, H. A., Bronsky, E. A., Furukawa, C. T. et al. A Dose-Ranging Study of Fluticasone Propionate Aqueous Nasal Spray for Seasonal Allergic Rhinitis Assessed by Symptoms, Rhinomanometry, and Nasal Cytology. Journal of Allergy and Clinical Immunology. 86(2): 221-230, 1990. 10. World Anti-Doping Agency The 2012 Prohibited List. 8-24-2011. 11. World Anti-Doping Agency World Anti Doping Agency 2012 Medical Information on Sinusitis/Rhinosinusitis. 2012. 12. Daley-Yates, P. T., Kunka, R. L., Yin, Y., Andrews, S. M. et al. Bioavailability of Fluticasone Propionate and Mometasone Furoate Aqueous Nasal Sprays. European Journal of Clinical Pharmacology. 60(4): 265-268, 2004. 13. Daley-Yates, P. T. and Baker, R. C. Systemic Bioavailability of Fluticasone Propionate Administered As Nasal Drops and Aqueous Nasal Spray Formulations. British Journal of Clinical Pharmacology. 51(1): 103-105, 2001. 14. Greiner, A. N. and Meltzer, E. O. Overview of the Treatment of Allergic Rhinitis and Nonallergic Rhinopathy. Proceedings of the American Thoracic Society. 8(1): 121-131, 2011. 15. Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J. et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (in Collaboration With the World Health Organization, GA2LEN and AllerGen). Allergy: European Journal of Allergy and Clinical Immunology. 63(SUPPL. 86): 8-160, 2008. 16. Scadding, G. K., Lund, V. J., Jacques, L. A., and Richards, D. H. A Placebo-Controlled Study of Fluticasone Propionate Aqueous Nasal Spray and Beclomethasone Dipropionate in Perennial Rhinitis: Efficacy in Allergic and Non-Allergic Perennial Rhinitis. Clinical and Experimental Allergy. 25(8): 737-743, 1995. 17. Van As, A., Bronsky, E. A., Dockhorn, R. J., Grossman, J. et al. Once Daily Fluticasone Propionate Is As Effective for Perennial Allergic Rhinitis As Twice Daily Beclomethasone Diproprionate. Journal of Allergy and Clinical Immunology. 91(6): 1146-1154, 1993. 18. Storms, W., Yawn, B., and Fromer, L. Therapeutic Options for Reducing Sleep Impairment in Allergic Rhinitis, Rhinosinusitis, and Nasal Polyposis. Current Medical Research and Opinion. 23(9): 2135-2146, 2007. 19. Craig, T. J., Sherkat, A., and Safaee, S. Congestion and Sleep Impairment in Allergic Rhinitis. Current Allergy and Asthma Reports. 10(2): 113-121, 2010. 20. Sardana, N. and Craig, T. J. Congestion and Sleep Impairment in Allergic Rhinitis. Asian Pacific Journal of Allergy and Immunology. 29(4): 297-306, 2011.